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Introduction {#s1}
============

The number of meta-analyses published in recent years has dramatically increased [@pone.0115934-Bolland1], [@pone.0115934-Bastian1]. Partly, this is because systematic reviews and meta-analyses are considered the highest level of evidence, but it is also relatively easy to undertake and publish a meta-analysis [@pone.0115934-Siontis1]. However, many meta-analyses are not novel, and either reproduce or extend earlier analyses on the same topic- i.e. are overlapping. In a random sample of meta-analyses that were published in 2010 and included randomised trials, 67% had at least one other overlapping meta-analysis [@pone.0115934-Siontis1]. Overlapping meta-analyses may report discordant results and conclusions, particularly as the number of such analyses increases. The consequences of this include contradictory recommendations for clinical practice, confusion amongst clinicians and their patients, and public disenchantment with clinical science.

Discordant meta-analyses have been reported previously for a variety of interventions [@pone.0115934-Cook1]--[@pone.0115934-Thorlund1], and recommendations for assessing such meta-analyses are available [@pone.0115934-Jadad1]. These recommendations focus on the methods and quality of the review, both of which have become much more standardised since the recommendations were proposed. The effect of vitamin D supplements on fracture is the subject of a large number of meta-analyses [@pone.0115934-Bolland2]. In 2012, an individual patient data meta-analysis was the 21^st^ meta-analysis published on this topic, but identified only 14 relevant randomised controlled trials [@pone.0115934-Grey1]. Two recent clinical guidelines on vitamin D [@pone.0115934-IOM1], [@pone.0115934-Holick1], based on meta-analyses of the same clinical trials by independent groups, reached very different conclusions [@pone.0115934-Rosen1], [@pone.0115934-Holick2]. As a case study of overlapping meta-analyses, we conducted a detailed review of meta-analyses of vitamin D and fracture. We investigated differences between the meta-analyses by applying recommendations for comparing discordant overlapping meta-analyses. We focused on the quality and methodology of the meta-analyses with regard to trials included, trial data utilised, analytic approaches, and conclusions, and considered the implications these differences have for clinical practice, interpretation of existing meta-analyses and performance of future analyses.

Methods {#s2}
=======

Ethics statement {#s2a}
----------------

Ethical approval was not required for this work.

We searched PubMed in October 2013 for systematic reviews and meta-analyses of vitamin D with fracture as an outcome ([S1 Appendix](#pone.0115934.s001){ref-type="supplementary-material"}). We identified 24 meta-analyses, and analysed the most recent meta-analysis in each of the highest ranking general medical journals (Ann Intern Med, BMJ, Cochrane Database Syst Rev, JAMA, JAMA Intern Med, Lancet, NEJM). We chose this sample of meta-analyses because they are likely to have been conducted to the highest standard, as well as being the most closely scrutinised during peer review and post-publication. Thus, we analysed 5 trial-level and 2 patient-level meta-analyses on the effect of vitamin D with or without calcium on fracture [@pone.0115934-BischoffFerrari1]--[@pone.0115934-BischoffFerrari3].

Jadad and colleagues recommended assessing discordant systematic reviews in 6 domains- the clinical question asked, study selection and inclusion, data extraction, study quality, ability to combine studies, and statistical methods [@pone.0115934-Jadad1]. Following this approach, the quality of each meta-analysis was assessed using the AMSTAR tool [@pone.0115934-Shea1], and the inclusion and exclusion criteria, endpoints, trials included, and data on hip and total fracture outcomes for each contributing study were extracted by one author (MB) and checked by a second (AG). Differences were resolved by consensus. Some trials reported data for non-vertebral fracture rather than total fracture. In this situation, we used data for non-vertebral fracture when total fracture data were not available. Only one meta-analysis described the reasons for exclusion of individual trials in detail [@pone.0115934-Avenell1]. For each of the other meta-analyses, we assessed whether trials that were not included in the meta-analysis were eligible for inclusion according to the published inclusion and exclusion criteria, and tried to determine why the trial was not included. Where data for the efficacy of vitamin D on fracture outcomes for a trial differed between meta-analyses, we tried to determine the reason. The recommended approach to analysis of a randomised controlled trial is an unadjusted intention-to-treat analysis using all randomised participants with data from the final study timepoint [@pone.0115934-ICH1]. We considered the result from this approach to be the best estimate of treatment efficacy. An analysis restricted to those participants who completed the study was termed a "per-protocol analysis." Finally, we compared the conclusions of the meta-analyses, with each author independently rating the strength of the conclusions toward the use of vitamin D supplementation to prevent fracture on a three point scale (positive/mixed/negative toward vitamin D supplementation) and on a scale from 1 to 5 (1 most negative, 5 most positive toward vitamin D supplementation). These ratings were based solely on the conclusions of the meta-analysis, and did not consider the data or analyses used in the meta-analyses.

Results {#s3}
=======

[Table 1](#pone-0115934-t001){ref-type="table"} shows the characteristics of the 7 meta-analyses and the trials included in each meta-analysis. The number of included trials in each meta-analysis ranged from 7 to 20. Of the 25 trials included in any of the meta-analyses [@pone.0115934-Chapuy1]--[@pone.0115934-Sanders1], 6 were included in only 1 meta-analysis, 3 in 2 meta-analyses, 2 in 3 meta-analyses, 3 in 4 meta-analyses, 7 in 5 meta-analyses, and 4 in 6 meta-analyses. No trial was included in all meta-analyses. The number of trials that met criteria for inclusion but were not included in each meta-analysis ranged from 0 to 8 trials: 4 meta-analyses included all trials that met the eligibility criteria [@pone.0115934-BischoffFerrari1]--[@pone.0115934-Avenell1], [@pone.0115934-DIPART1], with 2 meta-analyses "missing" 3 trials [@pone.0115934-BischoffFerrari2], [@pone.0115934-BischoffFerrari3], and 1 missing 8 trials [@pone.0115934-Chung1]. Of the 8 trials that were missing from at least 1 meta-analysis, 4 were missed in 1 meta-analysis, 2 in 2 meta-analyses, and 2 in 3 meta-analyses. Two meta-analyses [@pone.0115934-BischoffFerrari1], [@pone.0115934-Tang1] included 1 and 3 trials, respectively, that did not appear to meet the stated eligibility criteria ([Table 1](#pone-0115934-t001){ref-type="table"}). In both cases, other trials were not included in the meta-analyses despite having similar design to the included trials that appeared ineligible.

10.1371/journal.pone.0115934.t001

###### Characteristics of 7 included meta-analyses and trials included or excluded in each meta-analysis.

![](pone.0115934.t001){#pone-0115934-t001-1}

  Author                                                               Bischoff-Ferrari, 2005 [@pone.0115934-BischoffFerrari1]    Tang, 2007 [@pone.0115934-Tang1]     Bischoff-Ferrari, 2009 [@pone.0115934-BischoffFerrari2]   Avenell, 2009 [@pone.0115934-Avenell1]   DIPART, 2010 [@pone.0115934-DIPART1]       Chung, 2011 [@pone.0115934-Chung1]        Bischoff-Ferrari, 2012 [@pone.0115934-BischoffFerrari3]
  ------------------------------------------------------------------- --------------------------------------------------------- ------------------------------------- --------------------------------------------------------- ---------------------------------------- -------------------------------------- --------------------------------------------- ---------------------------------------------------------
  **Level of data**                                                                             Trial                                           Trial                                           Trial                                            Trial                                  Patient                                     Trial                                              Patient
  **Search end date**                                                                         Jan 2005                                        Jan 2007                                        Aug 2008                                         Sept 2007                               July 2008                                  July 2011                                           Aug 2011
  **Inclusion criteria**                                                                  Vit D+/− calcium                                 Vit D+ calcium                                 Vit D+/− calcium                                  Vit D+/− calcium                        Vit D+/− calcium                          Vit D+/− calcium                                    Vit D+/− calcium
                                                                                         Double-blind trials                          Placebo-controlled trials                           Oral supplements                                      Men\>65                                  N≥1000                                   \>1 month                                       Oral supplements
                                                                                          Oral supplements                                    Age ≥50 y                                        ≥1 year                                    Postmenopausal women                                                                                                                        Age ≥65 y
                                                                                               ≥1 year                                                                                       ≥1 fracture                                                                                                                                                      
                                                                                             ≥1 fracture                                                                                   Mean age ≥65 y                                                                                                                                                     
                                                                                           Mean age\>60 y                                                                                                                                                                                                                                                     
  **Exclusion criteria**                                                                   Major morbidity                             Secondary osteoporosis                              Major morbidity                                  Glucocorticoids                          Data censored                                Pregnancy                                      Untreated controls
                                                                                                                                                                                                                                           Factorial studies                            at 36 m                                Major morbidity                
                                                                                                                                                                                                                                            (except calcium)                                                                                                  
  **Endpoints (fracture)**                                                                       Hip                                            Total                                       Non-vertebral                                         Hip                                    Total                                      Total                                                Hip
                                                                                            Non-vertebral                                                                                        Hip                                         Non-vertebral                                Hip                                                                                       Non-vertebral
                                                                                                                                                                                                                                               Vertebral                                                                                                      
                                                                                                                                                                                                                                                 Total                                                                                                        
  **Included Trials**                                                                                                                                                                                                                                                                                                                                         
  Chapuy 1992/1994 [@pone.0115934-Chapuy1], [@pone.0115934-Chapuy2]                              Yes                                             Yes                                             Yes                                              Yes                                    X- NDA                                      Yes                                                 Yes
  Lips 1996 [@pone.0115934-Lips1]                                                                Yes                                           X-agent                                           Yes                                              Yes                                    X- NDA                                      Yes                                                 Yes
  Dawson-Hughes 1997 [@pone.0115934-DawsonHughes1]                                               Yes                                             Yes                                             Yes                                              Yes                                    X-size                                      Yes                                                 Yes
  Komulainen 1998 [@pone.0115934-Komulainen1]                                                   X-age                                          X-agent                                          X-age                                             Yes                                    X-size                                      Yes                                                X-age
  Pfeifer 2000 [@pone.0115934-Pfeifer1]                                                          Yes                                           X-agent                                           Yes                                              Yes                                    X-size                                      Yes                                                 Yes
  Chapuy 2002 [@pone.0115934-Chapuy3]                                                            Yes                                             Yes                                             Yes                                              Yes                                    X-size                                      Yes                                                X-NDA
  Meyer 2002 [@pone.0115934-Meyer1]                                                              Yes                                           X-agent                                           Yes                                              Yes                                     Yes                                    X-uncertain                                             Yes
  Bischoff 2003 [@pone.0115934-Bischoff1]                                                    X-duration                                        X-agent                                       X-duration                                           Yes                                    X-size                                  X-uncertain                                         X-uncertain
  Trivedi 2003 [@pone.0115934-Trivedi1]                                                          Yes                                           X-agent                                           Yes                                              Yes                                    X- NDA                                      Yes                                                X-NDA
  Avenell 2004 [@pone.0115934-Avenell2]                                                       X-design                                        X-design                       X-uncertain[a](#nt102){ref-type="table-fn"}                          Yes                                    X-size                  X-uncertain[a](#nt102){ref-type="table-fn"}                         X-controls
  Harwood 2004 [@pone.0115934-Harwood1]                                                       X-design                           Yes[b](#nt103){ref-type="table-fn"}                          Secondary                                           Yes                                    X-size                                      Yes                                             X-controls
  Larsen 2004 [@pone.0115934-Larsen1]                                         Secondary[b](#nt103){ref-type="table-fn"}          Yes[b](#nt103){ref-type="table-fn"}                          Secondary                                         X-design                                  Yes                                    X-uncertain                                         X-controls
  Flicker 2005 [@pone.0115934-Flicker1]                                                       Secondary                                        X-agent                                           Yes                                              Yes                                    X-size                                      Yes                                                 Yes
  Grant 2005 [@pone.0115934-Grant1]                                                            X-date                                            Yes                                             Yes                                              Yes                                     Yes                                        Yes                                                 Yes
  Law 2006 [@pone.0115934-Law1]                                                                X-date                                          X-agent                                        Secondary                                           Yes                                    X- NDA                                      Yes                                             X-controls
  Jackson 2006 [@pone.0115934-Jackson1]                                                        X-date                                            Yes                                             Yes                                              Yes                                     Yes                                        Yes                                                 Yes
  Porthouse 2006 [@pone.0115934-Porthouse1]                                                    X-date                            Yes[b](#nt103){ref-type="table-fn"}                          Secondary                                           Yes                                     Yes                                        Yes                                             X-controls
  Bolton-Smith 2007 [@pone.0115934-BoltonSmith1]                                               X-date                                          X-date                        X-uncertain[a](#nt102){ref-type="table-fn"}                          Yes                                    X-size                  X-uncertain[a](#nt102){ref-type="table-fn"}         X-uncertain[a](#nt102){ref-type="table-fn"}
  Lyons 2007 [@pone.0115934-Lyons1]                                                            X-date                                          X-date                                            Yes                                              Yes                                     Yes                                        Yes                                                 Yes
  Smith 2007 [@pone.0115934-Smith1]                                                            X-date                                          X-date                                           X-IM                                              Yes                                     Yes                                    X-uncertain                                            X-IM
  Prince 2008 [@pone.0115934-Prince1]                                                          X-date                                          X-date                                        X-uncertain                                          Yes                                    X-size                                  X-uncertain                                         X-uncertain
  Pfeifer 2009 [@pone.0115934-Pfeifer2]                                                       Secondary                                        X-date                                            Yes                                             X-date                                  X-date                                  X-uncertain                                             Yes
  Bischoff-Ferrari 2010 [@pone.0115934-BischoffFerrari4]                                       X-date                                          X-date                                          X-date                                            X-date                                  X-date                                   X-design                                               Yes
  Salovaara 2010 [@pone.0115934-Salovaara1]                                                    X-date                                          X-date                                          X-date                                            X-date                                  X-date                                      Yes                                             X-controls
  Sanders 2010 [@pone.0115934-Sanders1]                                                        X-date                                          X-date                                          X-date                                            X-date                                  X-date                                      Yes                                              Secondary

X =  study not included in meta-analysis. Reasons for non-inclusion: NDA- eligible for inclusion but no patient-level data available; agent- did not compare vitamin D plus calcium with placebo; size- study smaller than inclusion criteria allowed; age- age outside inclusion criteria; uncertain- unknown reason for exclusion; duration- duration of study less than inclusion criteria allowed; design- design did not meet inclusion criteria; controls- untreated control group; date- after search date; IM- intramuscular administration.

limited or no fracture data in primary publication, but data obtained from lead author and published in at least 1 meta-analysis. The Bolton-Smith fracture trial data were not published in Avenell 2009 until after publication of the Bischoff-Ferrari 2009 meta-analysis.

trial does not appear to meet eligibility criteria for meta-analysis.

Abbreviations: Secondary- included in secondary analyses only. Vit D: vitamin D.

[Table 2](#pone-0115934-t002){ref-type="table"} shows the quality assessment of each meta-analysis. Generally, the meta-analyses were of high quality, although all meta-analyses did not report some of the AMSTAR items, and some of the methods used in 3 meta-analyses [@pone.0115934-BischoffFerrari2], [@pone.0115934-Chung1], [@pone.0115934-BischoffFerrari3] were of uncertain validity. Reporting of AMSTAR items was less common in the 2 patient-level meta-analyses [@pone.0115934-DIPART1], [@pone.0115934-BischoffFerrari3].

10.1371/journal.pone.0115934.t002

###### Quality assessment of meta-analyses.

![](pone.0115934.t002){#pone-0115934-t002-2}

  AMSTAR item [@pone.0115934-Shea1]                                       Bischoff-Ferrari, 2005 [@pone.0115934-BischoffFerrari1]   Tang, 2007 [@pone.0115934-Tang1]   Bischoff-Ferrari, 2009 [@pone.0115934-BischoffFerrari2]   Avenell, 2009 [@pone.0115934-Avenell1]   DIPART, 2010 [@pone.0115934-DIPART1]   Chung, 2011 [@pone.0115934-Chung1]   Bischoff-Ferrari, 2012 [@pone.0115934-BischoffFerrari3]
  ---------------------------------------------------------------------- --------------------------------------------------------- ---------------------------------- --------------------------------------------------------- ---------------------------------------- -------------------------------------- ------------------------------------ ---------------------------------------------------------
  1\. A priori design                                                                               Yes                                           Yes                                            Yes                                              Yes                                     Yes                                   Yes                                             Yes
  2\. Duplicate study selection                                                                 Not stated                                     Not stated                                    Not stated                                           Yes                                  Not stated                            Not stated                                     Not stated
  2\. Duplicate data extraction                                                                     Yes                                           Yes                                            Yes                                              Yes                                Not applicable                             Yes                                       Not applicable
  3\. Comprehensive literature search                                                               Yes                                           Yes                                            Yes                                              Yes                      No[a](#nt105){ref-type="table-fn"}    No[a](#nt105){ref-type="table-fn"}             No[a](#nt105){ref-type="table-fn"}
  4\. Status of publication used as an inclusion criterion                                          No                                             No                                            No                                                No                                      No                                   Yes                                             No
  5\. List of included studies                                                                      Yes                                           Yes                                            Yes                                              Yes                                     Yes                                   Yes                                             Yes
  5\. List of excluded studies                                                                      No                                             No                                            No                                               Yes                                      No                                    No                                             No
  6.Characteristics of included studies reported                                                    Yes                                           Yes                                            Yes                                              Yes                                     Yes                                   Yes                                             No
  7\. Quality of studies assessed                                                                   Yes                                           Yes                                            Yes                                              Yes                                      No                                   Yes                                             No
  8\. Quality of studies used appropriately in formulating conclusions                              Yes                                           Yes                                            Yes                                              Yes                                      No                                   Yes                                             No
  9\. Appropriate methods used to combine results                                                   Yes                                           Yes                            No[b](#nt106){ref-type="table-fn"}                               Yes                                     Yes                    No[c](#nt107){ref-type="table-fn"}             No[d](#nt108){ref-type="table-fn"}
  10\. Publication bias assessed                                                                    Yes                                           Yes                                            Yes                                              Yes                                      No                                    No                                             No
  11\. Conflict of interests noted for review                                                       Yes                                           Yes                                            Yes                                              Yes                                     Yes                                   Yes                             Yes[e](#nt109){ref-type="table-fn"}
  11\. Conflict of interests noted for included studies                                             No                                             No                                            No                                                No                                      No                                    No                                             No

No search for grey literature described.

Data combined appropriately using random-effects models, but studies grouped according to received dose (treatment dose \* adherence). The advisability and validity of this approach is uncertain.

Data combined appropriately using random-effects models, but data for hip fracture was used for 4/16 trials when the primary endpoint assessed was total fracture.

Data combined appropriately using Cox proportional-hazards models, but method of assessment of vitamin D intake differed between treatment and control groups.

Partly funded by a manufacturer of vitamin D supplements.

[Tables 3](#pone-0115934-t003){ref-type="table"} and [4](#pone-0115934-t004){ref-type="table"} show data from each trial used in each meta-analysis for hip fracture and total fracture, respectively. For hip fracture, the relative risk differed between meta-analyses for 6 of 12 trials for which data were reported in two or more meta-analyses, and for total fracture, the relative risk differed between meta-analyses in 10 of 15 trials. [Tables 3](#pone-0115934-t003){ref-type="table"} and [4](#pone-0115934-t004){ref-type="table"} show the reasons for the differences in relative risks between the meta-analyses, which are summarised in [Table 5](#pone-0115934-t005){ref-type="table"}. Many of the differences arose when results obtained using analyses other than the recommend approach (unadjusted intention-to-treat analysis of all participants with data from the final study timepoint) were used in a meta-analysis, with the most common example being the use of a per-protocol analysis. The majority of the differences (4 of 6 for hip fracture, 7 of 10 for total fracture) led to more favourable estimates of the efficacy of vitamin D on hip or total fracture being used for individual trials than if the recommended approach was applied. In general, the Cochrane review [@pone.0115934-Avenell1] was most likely to use the recommended approach, and the relative risks used for each study in that review are the most conservative.

10.1371/journal.pone.0115934.t003

###### Data for hip fracture in each meta-analysis.

![](pone.0115934.t003){#pone-0115934-t003-3}

                                                                                   Bischoff-Ferrari 2005 [@pone.0115934-BischoffFerrari1]                  Bischoff-Ferrari 2009 [@pone.0115934-BischoffFerrari2]                          Avenell 2009 [@pone.0115934-Avenell1]                                                       Chung 2011 [@pone.0115934-Chung1]                                 
  ----------------------------------------------------------------------------- ------------------------------------------------------------ ---------- ------------------------------------------------------------- ----------- -------------------------------------------------------- ----------- ------------------------------------------------------------------------------------------------- ----------
  **Chapuy, 1992/1994** [@pone.0115934-Chapuy1], [@pone.0115934-Chapuy2]                                  137/1176                            178/1127                            137/1176                             178/1127                           137/1634                          178/1636                                                80/1387                                               110/1403
                                                                                 **0.74 (0.60--0.91)^b,^** [c](#nt116){ref-type="table-fn"}              **0.738 (0.6--0.907)^b,^** [c](#nt116){ref-type="table-fn"}                              **0.77 (0.62--0.95)^b^**                              **0.74 (0.56--0.97)** [c](#nt116){ref-type="table-fn"} **^,^** [d](#nt117){ref-type="table-fn"}  
  **Lips, 1996** [@pone.0115934-Lips1]                                                                    58/1291                             48/1287                              58/1291                              48/1287                           58/1291                            48/1287                                                58/1291                                               48/1287
                                                                                                     1.21 (0.83--1.75)                                                      1.205 (0.829--1.751)                                                     1.20 (0.83--1.75)                                                                         1.20 (0.83--1.75)                                         
  **Dawson-Hughes, 1997** [@pone.0115934-DawsonHughes1]                                                    0/187                               1/202                          Data not included                                                            0/187                              1/202                                            Data not included                                         
                                                                                                             NS                                  NS                                                                                                                                                                                                                                                      
  **Pfeifer, 2000** [@pone.0115934-Pfeifer1]                                                                0/70                                1/67                          Data not included                                                      Data not included                                                                         Data not included                                         
                                                                                                             NS                                  NS                                                                                                                                                                                                                                                      
  **Chapuy, 2002** [@pone.0115934-Chapuy3]                                                                 27/393                              21/190                              27/393                               21/190                             27/389                            21/194                                                 27/393                                                 21/190
                                                                                   **0.62 (0.36--1.07)** [e](#nt118){ref-type="table-fn"}                 **0.622 (0.362--1.068)** [e](#nt118){ref-type="table-fn"}                                **0.64 (0.37--1.10)**                                                    **0.62 (0.36--1.07)** [e](#nt118){ref-type="table-fn"}                       
  **Meyer, 2002** [@pone.0115934-Meyer1]                                                                   50/569                              47/575                              50/569                               47/575                             50/569                            47/575                                           Study not included                                         
                                                                                                     1.08 (0.73--1.57)                                                      1.075 (0.734--1.574)                                                     1.08 (0.73--1.57)                                                                                                                                   
  **Bischoff, 2003** [@pone.0115934-Bischoff1]                                                         Study excluded                                                          Study excluded                                                               2/62                              1/60                                            Study not included                                         
                                                                                                                                                                                                                                                     1.94 (0.18--20.79)                                                                                                                                  
  **Trivedi, 2003** [@pone.0115934-Trivedi1]                                                              21/1345                             24/1341                              21/1345                              24/1341                           21/1345                            24/1341                                           Data not included                                         
                                                                                   **0.85 (0.47--1.53)** [f](#nt119){ref-type="table-fn"}                  **0.85 (0.47--1.53)** [f](#nt119){ref-type="table-fn"}                                  **0.87 (0.49--1.56)**                                                                                                                                 
  **Avenell, 2004** [@pone.0115934-Avenell2] [a](#nt114){ref-type="table-fn"}                          Study excluded                                                        Study not included                                                                                                                                               Study not included                                         
  Vit D vs placebo                                                                                                                                                                                                                                          0/35                              1/35                                                                                                       
                                                                                                                                                                                                                                                      0.33 (0.01--7.91                                                                                                                                   
  CaD vs placebo                                                                                                                                                                                                                                            1/35                              1/35                                                                                                       
                                                                                                                                                                                                                                                     1.00 (0.07--15.36)                                                                                                                                  
  **Harwood, 2004** [@pone.0115934-Harwood1] [a](#nt114){ref-type="table-fn"}                          Study excluded                                                        Study not included                                                                                                                                                                                                          
  Vit D vs placebo                                                                                                                                                                                                                                          0/38                              1/37                                                   3/39                                                   5/37
                                                                                                                                                                                                                                                   **0.32 (0.01--7.73)**                                                    **0.57 (0.15--2.22)** [g](#nt120){ref-type="table-fn"}                       
  CaD vs placebo                                                                                                                                                                                                                                            1/75                              1/37                                                                                                       
                                                                                                                                                                                                                                                     0.49 (0.03--7.67)                                                                                                                                   
  **Grant, 2005** [@pone.0115934-Grant1] [a](#nt114){ref-type="table-fn"}                              Study excluded                                                                                                                                                                                                                          Data not included                                         
  Vit D vs placebo                                                                                                                                                                                                                                        47/1343                            41/1332                                                                                                     
                                                                                                                                                                                                                                                     1.14 (0.75--1.72)                                                                                                                                   
  CaD vs placebo                                                                                                                                                                                                                                          46/1306                            41/1332                                                                                                     
                                                                                                                                                                                                                                                     1.14 (0.76--1.73)                                                                                                                                   
  Vit D vs no Vit D                                                                                                                                                                93/2649                              90/2643                                                                                                                                                                          
                                                                                                                                                                            1.031 (0.776--1.371)                                                                                                                                                                                                         
  **Law, 2006** [@pone.0115934-Law1]                                                                   Study excluded                                                              24/1762                              20/1955                           17/1252                            14/1389                                                24/1762                                               20/1955
                                                                                                                                                                          **1.331 (0.740--2.397)**                                 **1.35 (0.67--2.72)** [h](#nt121){ref-type="table-fn"}                                                    **1.33 (0.74--2.40)**                                       
  **Jackson, 2006** [@pone.0115934-Jackson1]                                                           Study excluded                                                             146/11448                            186/11412                         175/18176                          199/18106                                          Data not included                                         
                                                                                                                                                          **0.782 (0.631--0.970)** [i](#nt122){ref-type="table-fn"}                                **0.88 (0.72--1.07)**                                                                                                                                 
  **Porthouse, 2006** [@pone.0115934-Porthouse1]                                                       Study excluded                                                              8/1321                               17/1993                            8/1321                            17/1993                                           Data not included                                         
                                                                                                                                                                            0.710 (0.309--1.633)                                                     0.71 (0.31--1.64)                                                                                                                                   
  **Lyons, 2007** [@pone.0115934-Lyons1]                                                               Study excluded                                                             112/1725                             104/1715                           112/1725                          104/1715                                           Data not included                                         
                                                                                                                                                                            1.071 (0.827--1.386)                                                     1.07 (0.83--1.39)                                                                                                                                   
  **Smith, 2007** [@pone.0115934-Smith1]                                                               Study excluded                                                          Study excluded                                                             66/4727                            44/4713                                          Study not included                                         
                                                                                                                                                                                                                                                     1.50 (1.02--2.19)                                                                                                                                   

Data for hip fracture were not analysed in Tang 2007 [@pone.0115934-Tang1], and individual trial data for hip fracture were not reported in DIPART 2010 [@pone.0115934-DIPART1], or Bischoff-Ferrari 2012 [@pone.0115934-BischoffFerrari3]. No data on hip fractures were reported in any meta-analysis for Komulainen 1998 [@pone.0115934-Komulainen1], Larsen 2004 [@pone.0115934-Larsen1], Flicker 2005 [@pone.0115934-Flicker1], Bolton-Smith 2007 [@pone.0115934-BoltonSmith1], Prince 2008 [@pone.0115934-Prince1], Pfeifer 2009 [@pone.0115934-Pfeifer2], Bischoff-Ferrari 2010 [@pone.0115934-BischoffFerrari4], Salovaara 2010 [@pone.0115934-Salovaara1], and Sanders 2010 [@pone.0115934-Sanders1].

Study excluded- study met meta-analysis exclusion criteria. Study not included- study did not meet exclusion criteria but not included in meta-analysis. Data not included- data not included in meta-analysis but available from other meta-analyses or primary publication.

Abbreviations: Vit D- vitamin D, RR- relative risk, CI confidence interval. NS- not stated. Vit D- vitamin D. CaD- co-administered calcium and vitamin D.

Bold text- indicates differences in relative risks for individual studies between meta-analyses.

factorial/multi-arm studies permitting multiple comparisons between randomised groups.

Reasons for differences in reported data between meta-analyses: ^b^data after 36 month from Chapuy 1994;

per-protocol analysis (all randomised participants not included);

data after 18 month from Chapuy 1992;

original paper reports different numbers for placebo group, correct numbers confirmed by original authors in Avenell 2009;

age-adjusted relative risk;

data for total fracture not hip fracture;

adjustments to the number of participants with outcomes and denominators were made using an intraclass correlation coefficient of 0.026 to account for cluster randomisation;

subgroup of participants only.

10.1371/journal.pone.0115934.t004

###### Data for total or non-vertebral fracture in each meta-analysis.

![](pone.0115934.t004){#pone-0115934-t004-4}

                                                                                                       Bischoff-Ferrari 2005 [@pone.0115934-BischoffFerrari1]                                                                                           Tang 2007 [@pone.0115934-Tang1]                                                                                          Bischoff-Ferrari 2009 [@pone.0115934-BischoffFerrari2]                                                 Avenell 2009 [@pone.0115934-Avenell1]                                       Chung 2011 [@pone.0115934-Chung1]               
  ----------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------- ---------- ---------------------------------------------------------------------------------------------------------------------------------------------- ------- -------------------------------------------------------------------------------------------------------- ----------- ------------------------------------------------------------ ------------ ------------------------------------------------------------ ------------
  **Chapuy, 1992/1994** [@pone.0115934-Chapuy1], [@pone.0115934-Chapuy2]                                                      255/1176                                                 308/1127                                                                      NS/NS                                                                       NS/NS                                                  255/1176                                                  308/1127                             255/1634                             308/1636                        Data not included                       
                                                                                 **0.79 (0.69--0.92)^b,^** [c](#nt129){ref-type="table-fn"} **^,^** [d](#nt130){ref-type="table-fn"}              **0.75 (0.64--0.87)^b,^** [d](#nt130){ref-type="table-fn"} **^,^** [e](#nt131){ref-type="table-fn"} **^,^** [f](#nt132){ref-type="table-fn"}           **0.793 (0.687--0.916)^b,^** [c](#nt129){ref-type="table-fn"} **^,^** [d](#nt130){ref-type="table-fn"}               **0.83 (0.71--0.96)^b,^** [c](#nt129){ref-type="table-fn"}                                                                            
  **Lips, 1996** [@pone.0115934-Lips1]                                                                                        135/1291                                                 122/1287                                                                  Study excluded                                                                                                                         135/1291                                                  122/1287                             135/1291                             122/1287                        Data not included                       
                                                                                                                        1.10 (0.87--1.39)^b^                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
  **Dawson-Hughes, 1997** [@pone.0115934-DawsonHughes1]                                                                        11/202                                                   26/187                                                                       NS/NS                                                                       NS/NS                                                   11/187                                                    26/202                               11/187                               26/202                               11/187                               26/202
                                                                                                                        0.46 (0.24--0.88)^b^                                                                                                                  0.46 (0.23--0.90)^b^                                                                                                              0.457 (0.237--0.879)^b^                                                                          0.46 (0.23--0.90)^b^                                                      0.46 (0.23--0.90)^b^                     
  **Komulainen, 1998** [@pone.0115934-Komulainen1]                                                                         Study excluded                                                                                                                        Study excluded                                                                                                                      Study excluded                                                                                     11/116                               15/116                               8/116                                14/116
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               **0.73 (0.35--1.53)^b^**                                 **0.57 (0.25--1.31)^b,^** [d](#nt130){ref-type="table-fn"}  
  **Pfeifer, 2000** [@pone.0115934-Pfeifer1]                                                                                    3/70                                                     6/67                                                                    Study excluded                                                                                                                           3/70                                                      6/67                                 3/74                                 6/74                                 3/70                                 6/67
                                                                                                     **0.48 (0.13--1.78)^b,^** [d](#nt130){ref-type="table-fn"}                                                                                                                                                                                                              **0.479 (0.129--1.782)^b,^** [d](#nt130){ref-type="table-fn"}                                                     **0.50 (0.13--1.92)^b^**                                 **0.48 (0.12--1.84)^b,^** [d](#nt130){ref-type="table-fn"}  
  **Chapuy, 2002** [@pone.0115934-Chapuy3]                                                                                     97/393                                                   55/190                                                                       NS/NS                                                                       NS/NS                                                   97/393                                                    55/190                               69/389                               34/194                         Data not included                       
                                                                                 **0.85 (0.64--1.13)^b,^** [f](#nt132){ref-type="table-fn"} **^,^** [g](#nt133){ref-type="table-fn"}                                  **0.85 (0.64--1.13)^b,^** [f](#nt132){ref-type="table-fn"} **^,^** [g](#nt133){ref-type="table-fn"}                                **0.853 (0.642--1.133)^b,^** [f](#nt132){ref-type="table-fn"} **^,^** [g](#nt133){ref-type="table-fn"}                                **1.01 (0.70--1.47)^b^**                                                                                             
  **Meyer, 2002** [@pone.0115934-Meyer1]                                                                                       69/569                                                   76/575                                                                   Study excluded                                                                                                                          69/569                                                    76/575                               69/569                               76/575                         Study not included                      
                                                                                                                        0.92 (0.68--1.24)^b^                                                                                                                                                                                                                                                    0.917 (0.677--1.244)^b^                                                                          0.92 (0.68--1.24)^b^                                                                                               
  **Trivedi, 2003** [@pone.0115934-Trivedi1]                                                                                   43/1345                                                 62/1341                                                                   Study excluded                                                                                                                         43/1345                                                    62/1341                             119/1345                             149/1341                             119/1345                             149/1341
                                                                                                       **0.67 (0.46--0.99)** [h](#nt134){ref-type="table-fn"}                                                                                                                                                                                                                    **0.67 (0.46--0.99)** [h](#nt134){ref-type="table-fn"}                                                         **0.80 (0.63--1.00)**                                                     **0.80 (0.63--1.00)**                     
  **Avenell, 2004** [@pone.0115934-Avenell2] [a](#nt127){ref-type="table-fn"}                                              Study excluded                                                                                                                        Study excluded                                                                                                                    Study not included                                                                                                                                                       Study not included                      
  Vit D vs placebo                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       3/35                                 5/35                                                                  
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 0.60 (0.16--2.32)^b^                                                                                               
  CaD vs placebo                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         3/35                                 5/35                                                                  
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 0.60 (0.16--2.32)^b^                                                                                               
  **Harwood, 2004** [@pone.0115934-Harwood1] [a](#nt127){ref-type="table-fn"}                                              Study excluded                                                                                                                                                                                                                                                                                                                                                                                                                                   Data not included                       
  Vit D vs placebo                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       0/38                                 5/37                                                                  
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 0.09 (0.01--1.55)^b^                                                                                               
  CaD vs placebo                                                                                                                                                                                                                                                     NS/NS                                                                       NS/NS                                                    3/39                                                      5/37                                 6/75                                 5/37                                                                  
                                                                                                                                                                                                                                             **0.49 (0.03--7.67)** [i](#nt135){ref-type="table-fn"}                                                                          **0.569 (0.148--2.185)^b,^** [j](#nt136){ref-type="table-fn"}                                    **0.59 (0.19--1.81)^b,^** [k](#nt137){ref-type="table-fn"}                                                                            
  **Larsen, 2004** [@pone.0115934-Larsen1]                                                                                      NS/NS                                                   NS/NS                                                                        NS/NS                                                                       NS/NS                                                  318/4957                                                  167/2116                          Study excluded                                                          Study not included                      
                                                                                                                                 NS                                                                                                            0.84 (0.72--0.98)[l](#nt138){ref-type="table-fn"}                                                                        NS[l](#nt138){ref-type="table-fn"} ^,^ [m](#nt139){ref-type="table-fn"}                                                                                                                                                                     
  **Flicker, 2005** [@pone.0115934-Flicker1]                                                                                    NS/NS                                                   NS/NS                                                                    Study excluded                                                                                                                          25/313                                                    35/312                               25/313                               35/312                               25/313                               35/312
                                                                                                                                 NS                                                                                                                                                                                                                                                               0.712 (0.438--1.158)                                                                            0.71 (0.44--1.16)                                                         0.71 (0.44--1.16)                       
  **Grant, 2005** [@pone.0115934-Grant1] [a](#nt127){ref-type="table-fn"}                                                  Study excluded                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
  Vit D vs placebo                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     188/1343                             179/1332                                                                
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  1.04 (0.86--1.26)[n](#nt140){ref-type="table-fn"}                                                                                 
  CaD vs placebo                                                                                                                                                                                                                                                     NS/NS                                                                       NS/NS                                                                                                                                                 165/1306                             178/1332                                                                
                                                                                                                                                                                                                                             **0.94 (0.77--1.15)** [n](#nt140){ref-type="table-fn"}                                                                                                                                                                             **0.95 (0.78--1.15)** [o](#nt141){ref-type="table-fn"}                                                                              
  Vit D vs no Vit D                                                                                                                                                                                                                                                                                                                                                                                     349/2649                                                  341/2643                                                                                                       387/2649                             377/2643
                                                                                                                                                                                                                                                                                                                                                                               **1.021 (0.888--1.174)** [p](#nt142){ref-type="table-fn"}                                                                                                                                  **1.02 (0.90--1.17)**                     
  **Law, 2006** [@pone.0115934-Law1]                                                                                       Study excluded                                                                                                                        Study excluded                                                                                                                         64/1762                                                    51/1955                             45/1252                              36/1389                         Data not included                       
                                                                                                                                                                                                                                                                                                                                                                                              **1.392 (0.971--1.997)^b^**                                                     **1.39 (0.90--2.14)^b,^** [q](#nt143){ref-type="table-fn"}                                                                            
  **Jackson, 2006** [@pone.0115934-Jackson1]                                                                               Study excluded                                                                                                                            NS/NS                                                                       NS/NS                                                 146/11448                                                  186/11412                           1921/18176                           1961/18106                           2102/18176                           2158/18106
                                                                                                                                                                                                                                                             **0.97 (0.92--1.03)**                                                                         **0.782 (0.631--0.970)** [r](#nt144){ref-type="table-fn"} **^,^** [s](#nt145){ref-type="table-fn"}                   **0.98 (0.92--1.04)** [t](#nt146){ref-type="table-fn"}                                    **0.97 (0.92--1.03)**                     
  **Porthouse, 2006** [@pone.0115934-Porthouse1]                                                                           Study excluded                                                                                                                            NS/NS                                                                       NS/NS                                                  58/1321                                                    91/1993                             58/1321                              91/1993                              58/1321                              91/1993
                                                                                                                                                                                                                                                               0.96 (0.70--1.33)                                                                                                                  0.962 (0.697--1.327)                                                                            0.96 (0.70--1.33)                                                 NS[u](#nt147){ref-type="table-fn"}              
  **Bolton-Smith, 2007** [@pone.0115934-BoltonSmith1]                                                                      Study excluded                                                                                                                        Study excluded                                                                                                                    Study not included                                                                                    2/62                                 2/61                          Study not included                      
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 0.98 (0.14--6.76)^b^                                                                                               
  **Lyons, 2007** [@pone.0115934-Lyons1]                                                                                   Study excluded                                                                                                                        Study excluded                                                                                                                         202/1725                                                  209/1715                             205/1725                             218/1715                             243/1670                             268/1673
                                                                                                                                                                                                                                                                                                                                                                               **0.961 (0.801--1.152)** [t](#nt146){ref-type="table-fn"}                                                        **0.93 (0.78--1.12)**                                     **0.91 (0.77--1.07)** [v](#nt148){ref-type="table-fn"}    
  **Smith, 2007** [@pone.0115934-Smith1]                                                                                   Study excluded                                                                                                                        Study excluded                                                                                                                      Study excluded                                                                                    306/4727                             279/4713                        Study not included                      
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 1.09 (0.93--1.28)^b^                                                                                               
  **Prince, 2008** [@pone.0115934-Prince1]                                                                                 Study excluded                                                                                                                        Study excluded                                                                                                                    Study not included                                                                                   4/151                                3/151                          Study not included                      
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  1.33 (0.30--5.86)                                                                                                 
  **Pfeifer, 2009** [@pone.0115934-Pfeifer2]                                                                                    NS/NS                                                   NS/NS                                                                    Study excluded                                                                                                                          9/121                                                     16/121                           Study excluded                                                          Study not included                      
                                                                                                                                NS^b^                                                                                                                                                                                                                                          0.563 (0.262--1.208)^b,^ [v](#nt148){ref-type="table-fn"}                                                                                                                                                                            
  **Salovaara, 2010** [@pone.0115934-Salovaara1]                                                                           Study excluded                                                                                                                        Study excluded                                                                                                                      Study excluded                                                                                 Study excluded                                                               78/1586                              94/1609
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            0.84 (0.63--1.13)                       
  **Sanders, 2010** [@pone.0115934-Sanders1]                                                                               Study excluded                                                                                                                        Study excluded                                                                                                                      Study excluded                                                                                 Study excluded                                                               171/1131                             135/1128
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            1.26 (1.02--1.56)[v](#nt148){ref-type="table-fn"}       

Data are for total fracture unless otherwise indicated. Individual trial data for fracture were not reported in DIPART 2010 [@pone.0115934-DIPART1], or Bischoff-Ferrari 2012 [@pone.0115934-BischoffFerrari3]. No data on total or non-vertebral fracture were reported in any meta-analysis for Bischoff 2003 [@pone.0115934-Bischoff1], and Bischoff-Ferrari 2010 [@pone.0115934-BischoffFerrari4].

Study excluded- study met meta-analysis exclusion criteria. Study not included- study did not meet exclusion criteria but not included in meta-analysis. Data not included- data not included in meta-analysis but available from other meta-analyses or primary publication.

Abbreviations: Vit D- vitamin D, RR- relative risk, CI confidence interval. NS- not stated. Vit D- vitamin D. CaD- co-administered calcium and vitamin D.

Bold text- indicates differences in relative risks for individual studies between meta-analyses.

factorial/multi-arm studies permitting multiple comparisons between randomised groups.

Reasons for differences in reported data between meta-analyses: ^b^non-vertebral fracture,

data after 36 month from Chapuy 1994;

per-protocol analysis (all randomised participants not included);

data after 18 month from Chapuy 1992;

hip fractures plus all non-vertebral fractures;

original paper reports different numbers for placebo group, correct numbers confirmed by original authors in Avenell 2009;

hip/wrist/forearm fracture used for non-vertebral fractures;

unknown how calculated;

excluded participants receiving intramuscular vitamin D;

includes participants receiving intramuscular vitamin D;

osteoporotic fracture;

fracture numbers calculated indirectly from [Table 3](#pone-0115934-t003){ref-type="table"} in meta-analysis;

low trauma fractures;

low trauma non-vertebral fractures;

participants with vertebral fracture subtracted from participants with low trauma fractures;

adjustments to the number of participants with outcomes and denominators were made using an intraclass correlation coefficient of 0.026 to account for cluster randomisation;

subgroup of participants only;

hip fractures used for non-vertebral fractures;

participants with vertebral fractures subtracted from participants with all fractures;

relative risk only reported for two subgroups,

total numbers of fractures (not numbers of participants with fracture).

10.1371/journal.pone.0115934.t005

###### Reasons for differences in results between meta-analyses, and effects on estimate of efficacy of vitamin D on fracture.
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  Reason                                                                                                                                                      Effect on estimate of vitamin D efficacy
  ---------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------
  **[Study selection and inclusion]{.ul}**                                                                                                                   
  • Eligible studies not included                                                                                                                                              Mixed
  • Ineligible studies included                                                                                                                                              Favourable
  **[Endpoint definition]{.ul}**                                                                                                                             
  • Inconsistent approach to endpoint definition                                                                                                                             Favourable
  (eg data for total fracture, hip fracture, total minus vertebral fracture, or hip/wrist/forearm fracture used inconsistently for non-vertebral fracture)   
  • Inconsistent approach to endpoint definition                                                                                                                             Favourable
  (eg data inconsistently restricted to low trauma fractures)                                                                                                
  **[Data extraction]{.ul}**                                                                                                                                 
  • Inconsistent data in original paper not checked with primary authors                                                                                                     Favourable
  • Use of data from early timepoint in study                                                                                                                                Favourable
  (instead of final timepoint)                                                                                                                               
  • Use of subgroups of participants                                                                                                                                         Favourable
  (instead of data for all randomised participants)                                                                                                          
  • Per-protocol analyses                                                                                                                                                    Favourable
  (instead of intention-to-treat)                                                                                                                            
  • Use of adjusted analyses                                                                                                                                                 Favourable
  (instead of primary unadjusted intention-to treat analysis)                                                                                                
  • Use of total numbers of fractures not numbers of participants with fractures                                                                                          Mixed-favourable
  **[Analytic approaches]{.ul}**                                                                                                                             
  • Pooling of data for mixed fracture types                                                                                                                              Mixed-favourable
  (eg hip and total fractures                                                                                                                                
  • Different approaches to handling data from cluster randomised controlled studies                                                                                          Neutral

The differences between meta-analyses in relative risks for individual trials were most prominent for the total or non-vertebral fracture endpoint. Non-vertebral fracture has commonly been reported in trials, but is often used interchangeably with total fracture. Some meta-analyses adopted this approach [@pone.0115934-Tang1], whereas others carried out separate analyses for total fracture and for non-vertebral fracture [@pone.0115934-Avenell1]. In several meta-analyses, there were inconsistent approaches to handling data ([Table 3](#pone-0115934-t003){ref-type="table"}). Participants with hip fracture were added to those with all non-vertebral fracture for 2 trials [@pone.0115934-Chapuy1], [@pone.0115934-Chapuy3] in one meta-analysis [@pone.0115934-Tang1], and for one of these two trials [@pone.0115934-Chapuy3] in two meta-analyses [@pone.0115934-BischoffFerrari1], [@pone.0115934-BischoffFerrari2], effectively counting hip fractures twice. In 2 meta-analyses [@pone.0115934-BischoffFerrari1], [@pone.0115934-BischoffFerrari2], the primary endpoint was non-vertebral fracture but, when this endpoint was not reported, the authors used different estimates of non-vertebral fractures for different individual trials. Thus [Table 4](#pone-0115934-t004){ref-type="table"} shows that for different trials the authors used total fracture; total fracture minus spine fracture; low trauma fracture minus spine fracture; hip, wrist, or forearm fracture; hip fracture; and counted hip fractures twice. For the 2 trials where only subsets of fractures were used (hip fracture, or hip/wrist/forearm fracture), data on total fractures were available. One meta-analysis utilised one fracture endpoint for each study determined hierarchically in descending order from total fracture, hip fracture, and non-vertebral fracture [@pone.0115934-Chung1]. For the resulting meta-analysis, total fracture was used for 10 trials, hip fracture for 4 trials, and non-vertebral fracture for 2 trials. Hip fracture is only a small subset of total fracture, and for all 4 trials where hip fracture was used, data on the broader endpoint of non-vertebral fracture were used in other meta-analyses.

[Table 6](#pone-0115934-t006){ref-type="table"} shows the conclusions from the meta-analysis. Some of the conclusions differ substantially. For example, in 3 meta-analyses Bischoff-Ferrari and colleagues conclude that higher doses but not lower doses of vitamin D prevent fractures [@pone.0115934-BischoffFerrari1], [@pone.0115934-BischoffFerrari2], [@pone.0115934-BischoffFerrari3], whereas 3 other meta-analyses concluded that vitamin D, used without calcium supplements, does not prevent fractures, regardless of the dose [@pone.0115934-Avenell1], [@pone.0115934-DIPART1], [@pone.0115934-Chung1]. [Table 6](#pone-0115934-t006){ref-type="table"} shows that our assessment of the strength of the conclusions in favour of vitamin D supplements ranged from mixed to strongly positive, with a median score of ≥4 for 6 of the 7 meta-analyses. The meta-analysis that most closely adhered to the recommended approach to analysis of a randomised controlled trial and fulfilled the most number of items in the AMSTAR tool had the least positive conclusion [@pone.0115934-Avenell1].

10.1371/journal.pone.0115934.t006

###### Conclusions of meta-analyses.
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  Author                                                                                                                 Conclusion                                                               Strength of Conclusion (Scale 1--5)[a](#nt149){ref-type="table-fn"}   Citations
  --------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------ --------------------------------------------------------------------- -----------
  Bischoff-Ferrari, 2005 [@pone.0115934-BischoffFerrari1]                   Vitamin D at a dose of 700--800 IU/d but not 400 IU/d reduces risk of hip and non-vertebral fracture                                            Positive (4.5)                                1270
  Tang, 2007 [@pone.0115934-Tang1]                                                                     CaD effectively prevents osteoporotic fracture                                                                       Positive (4.5)                                 816
  Avenell, 2009 [@pone.0115934-Avenell1]                            Vitamin D alone does not prevent fractures. CaD might prevent hip fractures in frail older institutionalised people                                        Mixed (3)                                   662
  Bischoff-Ferrari, 2009 [@pone.0115934-BischoffFerrari2]            Received dose of vitamin D of 482--770 IU/d but not ≤400 IU/d effectively prevents non-vertebral and hip fracture                                      Positive (4.5)                                 553
  DIPART, 2010 [@pone.0115934-DIPART1]                                          Vitamin D alone does not prevent fractures. CaD effectively prevents hip and total fractures                                                 Positive (4)                                  160
  Chung, 2011 [@pone.0115934-Chung1]                         CaD but not vitamin D alone can reduce fracture risk. Effects are smaller in community-dwelling than institutionalised individuals                                Mixed (4)                                   146
  Bischoff-Ferrari, 2012 [@pone.0115934-BischoffFerrari3]                                Vitamin D at a dose of ≥800 IU/d prevented hip and non-vertebral fracture.                                                          Positive (5)                                  205

Conclusions were rated independently by both authors. There was perfect agreement using the 3-point scale (positive/mixed/negative), and the median value on a 5 point scale is shown. Citations were obtained from Google Scholar in May 2014.

Discussion {#s4}
==========

Among overlapping meta-analyses of vitamin D and fracture, there were substantial differences in the trials included, the data used from each trial, the analytical approach adopted, and the conclusions drawn, despite the meta-analyses being of high quality and published in the highest ranking medical journals. Only 4 meta-analyses included all eligible trials, with the number of "missed" trials ranging from 3 to 8 in the other 3 meta-analyses. Two meta-analyses included trials that did not appear to meet eligibility criteria, while excluding other trials of similar design. The relative risks used for individual trials varied between meta-analyses, with differences being more common for total fracture (67% of trials) than for hip fracture (50% of trials). The differences in relative risks led to more favourable estimates of the efficacy of vitamin D compared to analyses using recommended analytic approaches on 11/16 (69%) occasions. The conclusions of the meta-analyses were discordant, ranging from strong statements that vitamin D prevents fractures to equally strong statements that vitamin D used without calcium does not prevent fractures. All meta-analyses were favourable toward prescribing of vitamin D for fracture prevention, although in some meta-analyses the recommendations were restricted to certain subgroups, or to co-administration of vitamin D with calcium supplements.

The reasons for the differences between the meta-analyses for the trials included and the data used ([Table 5](#pone-0115934-t005){ref-type="table"}) were often not readily apparent. An explanation as to why trials were not included was provided in only one meta-analysis. Fracture data for 3 of the trials included in the Cochrane review were unpublished and obtained for that review [@pone.0115934-Avenell1]. It is not clear whether the authors of other meta-analyses sought these unpublished data, or why, once published in the Cochrane review, they were not included in later meta-analyses. On a similar note, the Cochrane review authors clarified ambiguous reporting of treatment group numbers in the primary publication for one study with the lead author of the study [@pone.0115934-Chapuy3] ([Table 3](#pone-0115934-t003){ref-type="table"}/4), whereas in the other meta-analyses, incorrect denominators for both treatment groups were used.

The reasons for the differences in relative risks between meta-analyses can only be deduced by detailed, careful examination of the meta-analyses and the primary publications. One trial-level meta-analysis did not report the number of participants with fracture or the number of participants in each treatment group for individual trials [@pone.0115934-Tang1] and neither patient-level analysis [@pone.0115934-DIPART1], [@pone.0115934-BischoffFerrari3] reported these data or relative risks for individual trials. The absence of this information limits verification of the accuracy of the data and analyses undertaken. For patient-level analyses where data is censored at an earlier timepoint [@pone.0115934-DIPART1], this information is very important because the results at the earlier time point may differ from those of the overall trial. For example, in a patient-level meta-analysis of vitamin D and mortality [@pone.0115934-Rejnmark1], data for the Women\'s Health Initiative trial [@pone.0115934-Jackson1] was censored at 3 years, restricting the number of deaths to about 25% of those occurring in the trial, and providing a more favourable effect estimate than that for the entire follow-up. Several meta-analyses used data from per-protocol analyses for individual studies. The recommended analysis for a randomised controlled trial is an unadjusted intention-to-treat analysis including all available data from all randomised participants [@pone.0115934-ICH1]. We think the same principle applies in meta-analyses of randomised controlled trials. When only per-protocol data are reported for trials, the Cochrane handbook recommends performing sensitivity analyses to explore differences between intention-to-treat approaches (that assume participants lost to follow-up did not have an event), with results using per-protocol data [@pone.0115934-Higgins1]. None of the meta-analyses performed such sensitivity analyses. None of the meta-analyses provided sufficient details to permit a reader to understand if data from individual trials could be incorporated in the meta-analysis in different ways (such as using all fractures versus using only low-trauma fractures), and none compared their handling of the data with previous meta-analyses.

The methodological differences between meta-analyses influenced the conclusions drawn from them. Each of the 3 meta-analyses that considered trials of vitamin D with calcium supplements separately to trials of vitamin D [@pone.0115934-Avenell1], [@pone.0115934-DIPART1], [@pone.0115934-Chung1] concluded that vitamin D alone does not prevent fractures, regardless of dose. However, the 3 meta-analyses by Bischoff-Ferrari and colleagues that assessed vitamin D with or without calcium concluded that higher doses of vitamin D prevent fractures [@pone.0115934-BischoffFerrari1], [@pone.0115934-BischoffFerrari2], [@pone.0115934-BischoffFerrari3]. We have several reservations about the conclusions of these 3 meta-analyses. As highlighted in [Tables 3](#pone-0115934-t003){ref-type="table"} and [4](#pone-0115934-t004){ref-type="table"}, these meta-analyses used more favourable effect estimates for vitamin D for individual trials than estimates obtained using unadjusted intention-to-treat analysis of all participants with data from the final study timepoint. Most trials categorised as high dose vitamin D studied co-administered calcium and vitamin D, but the benefits were attributed to vitamin D. Three large trials of high dose vitamin D [@pone.0115934-Law1], [@pone.0115934-Smith1], [@pone.0115934-Sanders1] were excluded or only included in secondary analyses because of their study design, but all had relative risks for fracture with vitamin D greater than 1, essentially excluding clinically significant benefits on fracture prevention for vitamin D ([Tables 1](#pone-0115934-t001){ref-type="table"},[3](#pone-0115934-t003){ref-type="table"}--[4](#pone-0115934-t004){ref-type="table"}). Finally, 2 of these meta-analyses made questionable assumptions about received vitamin D doses and focused on treatment adherence analyses [@pone.0115934-BischoffFerrari2], [@pone.0115934-BischoffFerrari3], methodology that has been criticised [@pone.0115934-Abrahamsen1]. In our view, the Cochrane review [@pone.0115934-Avenell1] is the most detailed and comprehensive, receives the highest rating using the AMSTAR tool for quality assessment, includes the broadest range of trials, and utilises the recommended intention-to-treat approach with the most conservative effect estimates. We think the meta-analyses in the Cochrane review are the most reliable with the greatest external validity- i.e. the results are most generalisable to the wider population.

We followed the approach recommended in 1997 for assessment of discordance amongst systematic reviews [@pone.0115934-Jadad1]. The widespread use of checklists for reporting meta-analyses, such as the PRISMA checklist [@pone.0115934-Moher1], means that later meta-analyses have become more standardised and of higher quality. This is reflected in [Table 2](#pone-0115934-t002){ref-type="table"} which shows the high level of reporting of AMSTAR items used to assess meta-analysis quality. However, despite the apparent high quality of these meta-analyses, there were important differences in 3 of the domains that give rise to discordant meta-analyses [@pone.0115934-Jadad1]: study selection and inclusion, data extraction, and statistical methods. The differences are not readily apparent unless each meta-analysis is scrutinised in considerable detail. Thus, it is very likely that the casual reader, and even an expert reviewer, will not notice the differences or understand why the results of overlapping meta-analyses differ. Many of the methodological differences are based on subjective decisions made by the authors. Since different researchers make different judgements on these methodological issues, their decisions and the reasoning behind the decisions should be reported. In [Table 7](#pone-0115934-t007){ref-type="table"}, we propose additions to guidelines for the reporting of overlapping meta-analyses to facilitate their interpretation. They may also decrease redundant overlapping meta-analyses [@pone.0115934-Siontis1], by requiring authors to clearly identify previous publications and make apparent what the new meta-analyses adds to existing knowledge. An important limitation of our analysis is that it is limited to a single topic and a sample of meta-analyses published in high-impact journals, but it seems likely that the weaknesses in methodology and reporting we found will be present in other overlapping meta-analyses.

10.1371/journal.pone.0115934.t007

###### Suggestions for improved reporting of overlapping meta-analyses.

![](pone.0115934.t007){#pone-0115934-t007-7}

  -------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Abstract                                                                 • State article is an overlapping meta-analysis
                                                                                • State goal of current meta-analysis
  Introduction                                                           • Report number of previous meta-analyses on topic
                                                                          • Summarise conclusions of previous meta-analyses
                                                                                • State goal of current-meta-analysis
  Methods                                                                  • Reference all previous meta-analyses on topic
                                    • List all relevant studies identified in literature search not included in current meta-analysis, and reasons for exclusion
                                     • State which studies included in previous meta-analyses are excluded from current meta-analysis, and reasons for exclusion
                                 • State which studies included in current meta-analysis have not been included in previous meta-analyses, and reasons for inclusion
                          • State where data for individual studies in current meta-analysis differ from those used in previous meta-analyses, and reasons for differences
                  • For patient-level analyses, if data have been censored at an early time point, state whether estimates of effect size differ from estimates at final time point
  Results                                             • Data for numbers of events/participants reported (including for patient-level analyses)
  Discussion                                                               • Discuss conclusions of previous meta-analyses
                                                              • Discuss what current meta-analysis adds to existing body of literature
                                             • If conclusions of current meta-analysis differ from previous meta-analyses, state reasons for differences
  Registration                                         • Mandatory registration of meta-analysis protocol, including statistical analysis plan
  -------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------

There are important clinical consequences arising from discordant conclusions from overlapping meta-analyses. They engender confusion among clinicians and patients, and foster public disenchantment with biomedical research, exemplified by the statement often used in the media that "the experts can\'t make up their minds". Another specific possibility is that patients taking vitamin D supplements in the hope of preventing fractures might be falsely reassured that they are improving their skeletal health by the reporting of positive meta-analyses with methodological weaknesses or limited generalisability.

In summary, this detailed review reveals substantial differences between overlapping meta-analyses of vitamin D and fracture published in the highest ranking general medical journals, despite all meta-analyses generally being assessed as high quality using the AMSTAR tool. The reasons for these differences were often not readily apparent, but the differences led to more favourable estimates of the efficacy of vitamin D compared to estimates obtained using recommend analytic approaches. From this specific example, it is possible to propose additional guidelines for reporting meta-analyses, in order to create greater accuracy and transparency, especially amongst overlapping meta-analyses that report discordant results.
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